New insider activity at Surgery Partners ( (SGRY) ) has taken place on August 8, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CFO David T Doherty has made a significant move by selling 47,491 shares of Surgery Partners stock, amounting to a total transaction value of $1,110,814.
Recent Updates on SGRY stock
Surgery Partners recently announced its Q2 2025 earnings, reporting an 8.4% increase in revenue to $826.2 million and a 9% rise in Adjusted EBITDA to $129 million, despite a net loss of $2.5 million. The company emphasized strategic growth through same-facility revenue increases and physician recruitment, particularly in orthopedic procedures. Analysts have maintained a positive outlook, with a buy rating, citing strong operational performance and strategic expansions, despite challenges such as increased interest expenses and slower M&A activity. The resignation of Executive Chairman Wayne DeVeydt and subsequent leadership changes were noted, but the company remains confident in its growth trajectory and reaffirmed its full-year guidance.
Spark’s Take on SGRY Stock
According to Spark, TipRanks’ AI Analyst, SGRY is a Neutral.
Surgery Partners shows strong revenue and EBITDA growth, supported by strategic expansions and physician recruitment. However, profitability challenges, high leverage, and valuation concerns weigh on the stock. The technical indicators suggest a lack of strong momentum, while the earnings call provides a balanced outlook with both growth potential and risks.
To see Spark’s full report on SGRY stock, click here.
More about Surgery Partners
YTD Price Performance: 9.07%
Average Trading Volume: 1,679,935
Technical Sentiment Signal: Sell
Current Market Cap: $2.87B